These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 7872061)

  • 41. The influence of renal function on clinical pharmacokinetics of moxonidine.
    Kirch W; Hutt HJ; Plänitz V
    Clin Pharmacokinet; 1988 Oct; 15(4):245-53. PubMed ID: 3191647
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of cefodizime in normal individuals and in patients with renal failure.
    el Guinaidy MA; Nawishy S; Abd el Bary M; Sabbour MS
    Chemotherapy; 1991; 37(2):77-85. PubMed ID: 2032473
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantitative Assessment of the Effect of Chronic Kidney Disease on the Nonrenal Clearance of 10 Drugs After Intravenous Administration.
    Hinderling PH; Yu Y
    Clin Pharmacol Drug Dev; 2019 Feb; 8(2):138-151. PubMed ID: 30589517
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of iron on the absorption and distribution of clodronate after oral administration in rats.
    Osterman T; Juhakoski A; Laurén L; Sellman R
    Pharmacol Toxicol; 1994; 74(4-5):267-70. PubMed ID: 8090698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The tissue distribution of clodronate (dichloromethylene bisphosphonate) in mice. The effects of vehicle and the route of administration.
    Mönkkönen J; Ylitalo P
    Eur J Drug Metab Pharmacokinet; 1990; 15(3):239-43. PubMed ID: 2147646
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Level of clodronate in bone after single and repeated subcutaneous injections in rats.
    Osterman T; Laurén L
    Pharmacol Toxicol; 1991 Nov; 69(5):369-71. PubMed ID: 1839448
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of the thromboxane A2 receptor antagonist sulotroban (BM 13.177) in renal failure.
    Piper C; Staiger C; Jumeau-Ziemendorff Y; Uebis V; Kaufmann B; Stein K
    Br J Clin Pharmacol; 1989 Sep; 28(3):281-8. PubMed ID: 2528984
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clodronate kinetics and bioavailability.
    Yakatan GJ; Poynor WJ; Talbert RL; Floyd BF; Slough CL; Ampulski RS; Benedict JJ
    Clin Pharmacol Ther; 1982 Mar; 31(3):402-10. PubMed ID: 6460586
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clodronate kinetics and dynamics.
    Conrad KA; Lee SM
    Clin Pharmacol Ther; 1981 Jul; 30(1):114-20. PubMed ID: 6453676
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disposition of recombinant human interleukin-10 in subjects with various degrees of renal function.
    Andersen SR; Lambrecht LJ; Swan SK; Cutler DL; Radwanski E; Affrime MB; Garaud JJ
    J Clin Pharmacol; 1999 Oct; 39(10):1015-20. PubMed ID: 10516935
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay.
    Broughton A; Strong JE; Holoye PY; Bedrossian CW
    Cancer; 1977 Dec; 40(6):2772-8. PubMed ID: 73408
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease.
    Krens LL; Baas JM; Guchelaar HJ; Gelderblom H
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):179-182. PubMed ID: 29170802
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of cyclophosphamide in renal failure.
    Mouridsen HT; Jacobsen E
    Acta Pharmacol Toxicol (Copenh); 1975; 36(Suppl 5):409-14. PubMed ID: 1173530
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Spectrophotometric determination of clodronate with thorium-morin.
    Virtanen V; Lajunen LH
    Acta Chem Scand (Cph); 1993 Jan; 47(1):89-91. PubMed ID: 8424886
    [No Abstract]   [Full Text] [Related]  

  • 55. Circular RNA atlas in osteoclast differentiation with and without alendronate treatment.
    Lin J; Ma S; Zhu C; Chen C; Lin W; Lin C; Huang G; Ding Z
    J Orthop Surg Res; 2020 Jul; 15(1):240. PubMed ID: 32611361
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clodronate: new directions of use.
    Frediani B; Bertoldi I
    Clin Cases Miner Bone Metab; 2015; 12(2):97-108. PubMed ID: 26604933
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bisphosphonate therapy in metastatic carcinoma patients with chronic renal failure: are bisphosphonates an enemy or crony?
    Koseoglu FD; Arslan C
    Support Care Cancer; 2015 Jun; 23(6):1489-91. PubMed ID: 25763753
    [No Abstract]   [Full Text] [Related]  

  • 58. Clodronic acid formulations available in Europe and their use in osteoporosis: a review.
    Frediani B; Cavalieri L; Cremonesi G
    Clin Drug Investig; 2009; 29(6):359-79. PubMed ID: 19432497
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis.
    Cremers SC; Pillai G; Papapoulos SE
    Clin Pharmacokinet; 2005; 44(6):551-70. PubMed ID: 15932344
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of bisphosphonates in diseases of childhood.
    Srivastava T; Alon US
    Eur J Pediatr; 2003 Nov; 162(11):735-51. PubMed ID: 14523647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.